OFIX on Nasdaq

Orthofix Medical Inc.

Surgical and medical instruments and apparatus company, listed on Nasdaq (OFIX).

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Alphatec Holdings, Inc., iRhythm Holdings, Inc. or Inspire Medical Systems (United States), or pick any stock.

  • TickerOFIX on Nasdaq
  • IndustrySurgical & Medical Instruments & Apparatus
  • Business address3451 Plano Parkway, Lewisville, Tx 750562
  • Filer categoryAccelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

68.8%Gross margin3
-9.9%Operating margin3
-11.2%Net margin3
2.9%Revenue growth, 20253
-20.5%Return on equity3
0.35×Debt to equity3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Global Spine brought in 84% of the revenue Orthofix Medical Inc. broke down this way in fiscal 2025.

  1. Global Spine$687.7M384%up 2% from 2024
  2. Global Limb Reconstruction$134.7M316%up 8% from 2024
Business segments by year
Business segments202320242025
Global Spine$631.3M$675.3M$687.7M
Global Limb Reconstruction$115.3M$124.2M$134.7M

Regions

United States brought in 83% of the revenue Orthofix Medical Inc. broke down this way in fiscal 2025.

  1. United States$684.1M383%up 2% from 2024
  2. Other Countries$76.7M39%up 16% from 2024
  3. Italy$22.3M33%up 6% from 2024
  4. United Kingdom$13.3M32%up 19% from 2024
  5. France$12.0M31%down 11% from 2024
  6. Germany$9.1M31%up 1% from 2024
  7. Brazil$4.8M31%down 15% from 2024
Regions by year
Regions202320242025
United States$620.8M$672.8M$684.1M
Other Countries$65.8M$66.4M$76.7M
Italy$20.1M$21.0M$22.3M
United Kingdom$10.9M$11.2M$13.3M
France$11.1M$13.4M$12.0M
Germany$11.5M$9.0M$9.1M
Brazil$6.5M$5.7M$4.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue29¢$256.3M
  • Research and development8¢$65.8M
  • Selling, general and admin63¢$554.3M
  • Income tax0¢$1.4M

Out of $822.3M in revenue.3 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Kept or used elsewhere100¢$33.3M

Out of $33.3M of cash from operations.3

Financial statements

Revenue45673$822.3M in 2025+79% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $460.0M$460.0M20192020: $406.6M$406.6M2020−12%2021: $464.5M$464.5M2021+14%2022: $460.7M$460.7M2022−1%2023: $746.6M$746.6M2023+62%2024: $799.5M$799.5M2024+7%2025: $822.3M$822.3M2025+3%
Gross profit45673$566.0M in 2025+58% since 2019
0$200.0M$400.0M$600.0M2019: $359.3M$359.3M20192020: $304.7M$304.7M2020−15%2021: $349.6M$349.6M2021+15%2022: $337.2M$337.2M2022−4%2023: $486.3M$486.3M2023+44%2024: $545.9M$545.9M2024+12%2025: $566.0M$566.0M2025+4%
Operating income45673-$81.4M in 2025+333% since 2019
-$150.0M-$100.0M-$50.0M02019: -$18.8M-$18.8M20192020: -$6.3M-$6.3M2020−67%2021: -$8.3M-$8.3M2021+33%2022: -$13.3M-$13.3M2022+60%2023: -$139.1M-$139.1M2023+948%2024: -$84.6M-$84.6M2024−39%2025: -$81.4M-$81.4M2025−4%
Net income45673-$92.2M in 2025+224% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M0$50.0M2019: -$28.5M-$28.5M20192020: $2.5M$2.5M20202021: -$38.4M-$38.4M20212022: -$19.7M-$19.7M2022−49%2023: -$151.4M-$151.4M2023+667%2024: -$126.0M-$126.0M2024−17%2025: -$92.2M-$92.2M2025−27%

Every line of the income statement in the latest annual report, as filed.3

Period ending2025-12-312024-12-312023-12-31
Net sales$822.3M$799.5M$746.6M
Cost of sales$256.3M$253.6M$260.4M
Gross profit$566.0M$545.9M$486.3M
Sales, general, and administrative$554.3M$532.5M$530.4M
Research and development$65.8M$73.6M$80.2M
Acquisition-related amortization, impairment, and remeasurement (Note 17)$27.3M$24.3M$14.8M
Operating loss-$81.4M-$84.6M-$139.1M
Interest expense, net-$17.5M-$29.6M-$8.6M
Other (expense) income, net$8.1M-$9.6M-$938.0K
Loss before income taxes-$90.8M-$123.9M-$148.7M
Income tax expense-$1.4M-$2.1M-$2.7M
Net loss-$92.2M-$126.0M-$151.4M
Basic-$2.33-$3.30-$4.12
Diluted-$2.33-$3.30-$4.12
Basic39.6M shares38.1M shares36.7M shares
Diluted39.6M shares38.1M shares36.7M shares
Unrealized loss on debt securities-$1.3M
Currency translation adjustment$4.9M-$3.0M$1.4M
Other comprehensive income (loss), before tax$4.9M-$3.0M$83.0K
Other comprehensive income (loss), net of tax$4.9M-$3.0M$83.0K
Comprehensive loss-$87.3M-$129.0M-$151.3M

Compare Orthofix Medical Inc. with another company

Leadership

Who has led Orthofix Medical Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Charles Federico2006
  2. Alan Milinazzo2006–2011
  3. Robert S. Vaters2012–2013
  4. Jon Carl Serbousek2019–2022
  5. Keith Valentine2023
  6. Catherine M. Burzik2023
  7. Massimo Calafiore2024–now

Chair

  1. James Gero2006–2009
  2. Jon Carl Serbousek2023

President

  1. Charles Federico2006
  2. Gary Henley2006
  3. Alan Milinazzo2006–2011
  4. Bradley R. Mason2006–2009
  5. Oliver Burckhardt2006–2008
  6. Matthew Lyons2007
  7. Scott Dodson2007
  8. Luigi Ferrari2008–2012
  9. Kevin Unger2009
  10. Bryan McMillan2011–2012
  11. Michael Finegan2012
  12. Robert S. Vaters2012–2013
  13. Bradley Niemann V.2016–2019
  14. Raymond Fujikawa2016–2018
  15. Robert Allen Goodwin Ii.2016–2018
  16. Davide Bianchi2017–2019
  17. Jon Carl Serbousek2019
  18. Kevin J. Kenny2019–2024
  19. Paul Gonsalves2020–2022
  20. Kimberley A. Elting2022–2024
  21. Keith Valentine2023
  22. Massimo Calafiore2024
  23. Max Reinhardt2024
  24. Patrick Fisher2024–now

Chief financial officer

  1. Thomas M. Hein2006–2008
  2. Timothy M. Adams2007–2008
  3. Robert S. Vaters2008–2009
  4. Brian McCollum2011–2012
  5. Emily Buxton2012–2013
  6. David E. Ziegler2014
  7. Mark A. Heggestad2014
  8. Rice Doug2014–2022
  9. John J. Bostjancic2023
  10. Geoffrey C. Gillespie2023–2024
  11. Julie Andrews2024–now

Chief operating officer

  1. Alan Milinazzo2006
  2. Robert S. Vaters2011
2010201520202025
Board members and other officers (47)

Former names

  • ORTHOFIX INTERNATIONAL N VSep 3, 1998 to Aug 1, 20182

Timeline

  1. Jan 10, 2024New chief executive Massimo Calafiore becomes CEO11
  2. Oct 17, 2023New chief executive Catherine M. Burzik becomes CEO13
  3. Jan 9, 2023New chief executive Keith Valentine becomes CEO12
  4. Nov 5, 2019New chief executive Jon Carl Serbousek becomes CEO14
  5. Feb 16, 2012New chief executive Robert S. Vaters becomes CEO15
  6. Apr 12, 2006New chief executive Alan Milinazzo becomes CEO17
  7. Mar 7, 2006New chief executive Charles Federico becomes CEO16

Recent filings

  1. Oct 5, 20264
  2. Sep 23, 20264/A PRIMARY DOCUMENT
  3. Sep 22, 20264 PRIMARY DOCUMENT
  4. Sep 3, 20264
  5. Sep 1, 2026144
  6. Aug 20, 20264
  7. Aug 18, 20264 PRIMARY DOCUMENT
  8. Aug 14, 2026SCHEDULE 13G/A
  9. Aug 5, 20268-K
  10. Aug 5, 202610-Q
  11. Aug 5, 2026S-8
  12. Jul 2, 20268-K
  13. Jun 22, 20264
  14. Jun 12, 20264
  15. Jun 12, 20264

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95